At the end of the day, it won’t matter what any of us think. NEU have an independent valuation of the company. They have a corporate advisor. So when an offer lobs across their boardroom table they will either accept and recommend it or knock it back,
there comes a time in all business ventures when it’s time to call it a day and take your money off the table. NEU does not have the capital or resources to fully maximise the opportunity 2591 offers.
This drug needs serious investment to maximise its potential,, So a major licensing deal or a trade sale are the options
The recent consensus had NEU valued at ~$30! Add a takeover premium of 60% to that figure and we have $48. Or US $4bn.
That seem quite achievable. Remember back in 2020 most posters here were sure they’d never see $5. Most would have run for the door at $5. Now they wouldn’t be happy with $500!
NEU Price at posting:
$11.80 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)